The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.

Journal: PloS one
Published Date:

Abstract

INTRODUCTION: The ReIMAGINE Consortium was conceived to develop risk-stratification models that might incorporate the full range of novel prostate cancer (PCa) diagnostics (both commercial and academic).

Authors

  • Teresa Marsden
    UCL Division of Surgical & Interventional Sciences, University College London, London, United Kingdom.
  • Neil McCartan
    UCL Division of Surgical & Interventional Sciences, University College London, London, United Kingdom.
  • Louise Brown
    Department of Biomedical Imaging Science, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
  • Manuel Rodriguez-Justo
    Research Department of Pathology, University College London, London, United Kingdom.
  • Tom Syer
    Centre for Medical Imaging, University College London, London, United Kingdom.
  • Giorgio Brembilla
    Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Mieke Van Hemelrijck
    School of Cancer and Pharmaceutical Sciences, Kings College London, London, United Kingdom.
  • Ton Coolen
    London Institute for Mathematical Sciences, London, United Kingdom.
  • Gerhardt Attard
    Cancer Institute, University College London, London, United Kingdom.
  • Shonit Punwani
    Centre for Medical Imaging, University College London, 2nd Floor Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK. shonit.punwani@gmail.com.
  • Caroline M Moore
    Division of Surgery and Interventional Science, University College London, London, UK.
  • Hashim U Ahmed
    Division of Surgery and Interventional Science, University College London, London, UK.
  • Mark Emberton
    Division of Surgery and Interventional Science, University College London, London, UK.